The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.50
Bid: 65.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 5.00 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 67.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Termination of Formal Sales Process

15 Jan 2019 11:08

RNS Number : 1482N
NetScientific PLC
15 January 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

FOR IMMEDIATE RELEASE

15 January 2019

NetScientific plc

("NetScientific" or the "Company")

Termination of Formal Sales Process

 

On 20 December 2018, NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation group, announced, inter alia, that, following its decision to conduct a review of various strategic options open to it, announced on 26 November 2018, (the "Strategic Review"), it was not in receipt of any approaches, and that it was not then in discussions with any potential offeror concerning a sale of the Company.

This remains the case and the Board is not aware of any parties who might now make such an approach or initiate such discussions.

Accordingly, the Company confirms that it has closed the formal sale process under the City Code on Takeovers and Mergers (the "Takeover Code") that it had commenced as part of the Strategic Review.

Following this announcement, the Company is no longer considered to be in an "offer period" as defined in the Takeover Code and the requirement to make disclosures under Rule 8 of the Takeover Code has now ceased.

In light of the above, the Board continues to assess all of its remaining strategic options, including seeking additional funding from its shareholders and taking material action to reduce further the Company's costs, which may include seeking a delisting.

Further announcements will be made as appropriate.

For more information, please contact:

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave / Chris Viggor

 

Tel: +44 (0)20 7220 1666

 

Ondra (Financial Adviser)

Michael Tory / Michiel Bröker

 

Tel: +44 (0)20 7082 8827

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

NetScientific@consilium-comms.com

Tel: +44 (0)20 3709 5700

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

Important notices

Ondra LLP, which is regulated in the United Kingdom by the Financial Conduct Authority, is acting as joint financial adviser exclusively for NetScientific and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of Ondra LLP, nor for providing advice in relation to any matter referred to herein.

This announcement has been prepared by, and is the sole responsibility of the Directors of NetScientific. WH Ireland Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for NetScientific and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of WH Ireland Limited., or for providing advice in relation to the matters referred to in this announcement.

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Cautionary note regarding forward-looking statements

This announcement may contain certain forward-looking statements, beliefs or opinions, with respect to the financial condition, results of operations, financial performance, business strategy or plans for future operations the Company. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "hope", "aims", "continue", "will", "may", "should", "would", "could", or other words of similar meaning. These statements are based on assumptions and assessments made by the Company in light of their experience and their perception of historical trends, current conditions, future developments and other factors they believe appropriate.

By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this announcement could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement.

The Company does not assume any obligation to, and does not intend to, update or correct the information contained in this announcement (whether as a result of new information, future events or otherwise), except as required by applicable law. There are several factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax rates and future business combinations or disposals.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDKDBKDPDD
Date   Source Headline
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:36 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 20204:40 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:02 pmRNSPDS Initiates Programs for COVID-19, PDS0101 delay
14th Apr 20207:04 amRNSPDS Appoints Ilian Iliev to the Board
31st Mar 20207:00 amRNSBoard Changes
30th Mar 20209:39 amRNSHolding(s) in Company
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.